Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Seattle Genetics Inc (NASDAQ:SGEN)

56.57
Delayed Data
As of 3:59pm ET
 +0.86 / +1.54%
Today’s Change
26.02
Today|||52-Week Range
57.23
+26.05%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$7.8B

Company Description

Seattle Genetics, Inc. engages in the development and commercialization of monoclonal antibody-based therapies for cancer. Its product ADCETRIS or brentuximab vedotin has been approved by both U.S. Food and Drug Association and Health Canada in U.S. and Canada respectively. ADCETRIS is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Contact Information

Seattle Genetics, Inc.
21823 30th Drive SE
Bothell Washington 98021
P:(425) 527-4000
Investor Relations:
(425) 527-4160

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Clay B. SiegallChairman, President & Chief Executive Officer
Eric L. DobmeierChief Operating Officer
Todd E. SimpsonChief Financial Officer
Jonathan DrachmanChief Medical Officer, EVP-Research & Development
Peter D. SenterVice President-Chemistry